Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Super1 TCR-T in NY-ESO-1+ Advanced Solid Tumors
NCT06942143Phase 1Recruiting
- Sponsor
- Guangzhou FineImmune Biotechnology
- Start
- May 2025
- Primary completion
- Apr 2027
- Modality
- TCR-Engineered T Cells
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of Super1 TCR-T in sarcoma, lung cancer and melanoma, sponsored by Guangzhou FineImmune Biotechnology. Primary endpoints: Dose-Limiting Toxicity at 28 days and Maximum Tolerated Dose at 28 days. Started May 2025; status: recruiting.
02
Drugs
Super1 TCR-T
03
Conditions
sarcomalung cancermelanoma
Beyond the preview
Go deeper on NCT06942143.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06942143.